Our Broad and Disruptive Platform

We are delivering a new class of RNA therapies – Antibody Oligonucleotide Conjugates (AOCs). AOCs overcome current barriers to the delivery of oligonucleotides unlocking their potential to treat diseases currently lacking adequate treatment options and allowing us to address unmet patient needs. We have demonstrated preclinical proof of concept for AOCs in multiple tissues. We are broadening our research to other tissue and cell types through internal discovery efforts and partnerships.

Our Advancing and Expanding Pipeline

We are currently progressing a robust pipeline of skeletal muscle programs. Our first program, AOC 1001 is currently in Phase 1/2 development with the ongoing MARINA trial* in adults with myotonic dystrophy type 1 (DM1). All participants in the MARINA study are eligible to enroll in the open-label extension study, MARINA-OLETM. We also have received Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA) to initiate Phase 1/2 studies of AOC 1044 for people with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 44 skipping and AOC 1020 for people with facioscapulohumeral muscular dystrophy (FSHD). We now have three programs in clinical development.

*In Sept. 2022, Avidity announced that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA clinical trial of AOC 1001 in adults with DM1. All current participants, whether they are on AOC 1001 or placebo, may continue in their current dosing cohort although no additional participants may be enrolled until the partial clinical hold is resolved. All participants in MARINA may roll over into the MARINA-OLE where they will receive AOC 1001 as planned. Avidity is working closely with the FDA and the trial investigator to resolve the partial clinical hold on new participant enrollment as quickly as possible.

Beyond the clinical programs, we have research and development efforts focused on skeletal muscle, immune cells and additional cell types. We are driven to accelerate our research to tackle unmet needs and better serve patients and their families.

Our Agile and Diverse Company

Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.

We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.